The antiviral drug nirmatrelvir-ritonavir (Paxlovid) was linked to a lower risk of hospitalization within 30 days and major adverse cardiovascular events (MACEs) and death at 1 year in adults with ...

By Pam Belluck Pam Belluck has covered long Covid since the condition first emerged. Can Paxlovid treat long Covid? A new report suggests it might help some patients, but which patients might ...

The findings run counter to a clinical trial which found no benefit from Paxlovid in long COVID patients WEDNESDAY, Jan. 8, 2024 (HealthDay News) -- The antiviral pill Paxlovid might help some ...

Can Paxlovid treat long COVID? A new report suggests it might help some patients, but which patients might benefit remains unclear. The report, published last week in the journal Communications ...

A recent study from the University of California, San Francisco, offers a closer look at how some patients respond to extended courses of Paxlovid, a combination of nirmatrelvir and ritonavir.

A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long COVID when administered outside of an infection. Administration of Paxlovid ...

It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older ...

The findings run counter to a clinical trial which found no benefit from Paxlovid in long COVID patients WEDNESDAY, Jan. 8, 2024 (HealthDay News) -- The antiviral pill Paxlovid might help some ...

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty.

Among high-risk patients, treatment with paxlovid reduces the COVID-19 burden. Researchers conducted a phase 2/3, double-blind, randomized study (Evaluation of Protease Inhibition for COVID-19 in High ...